Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Program of belantamab mafodotin in relapsed/refractory multiple myeloma (Japan)
jRCT2031210607Recruiting
- Sponsor
- GSK
- Start
- Mar 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of belantamab mafodotin in multiple myeloma (MM) (3 arms), sponsored by GSK. Primary endpoints: Safety of belantamab mafodotin regimens and Efficacy of belantamab mafodotin regimens. Started Mar 2022; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031210607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210607.